What the FDA labels say about taking them together
Maribavir and sirolimus
Maribavir's FDA label of January 27, 2026 names sirolimus in its drug interactions section; the sirolimus labels PlainMeds reads (4) do not name maribavir. The maribavir label: “Frequently monitor sirolimus levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust dose, as needed.”
Check it at the source: the maribavir FDA label on DailyMed (effective January 27, 2026, Takeda Pharmaceuticals America, Inc.); the sirolimus FDA label on DailyMed (effective January 28, 2026, Glenmark Pharmaceuticals Inc., USA).
What does the maribavir label say about sirolimus?
Maribavir label, drug interactionsConcomitant Drug Class/Drug Name: Sirolimus; Effect on Concentration: ↑ Sirolimus; Clinical Comments: Frequently monitor sirolimus levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust dose, as needed.
Maribavir label, warnings and precautionsSome maribavir pUL97 resistance-associated substitutions confer cross-resistance to ganciclovir and valganciclovir. ( 5.2 , 12.4 , 14.1 ) The concomitant use of LIVTENCITY and certain drugs may result in potentially significant drug interactions, some of which may lead to reduced therapeutic effect of LIVTENCITY or adverse reactions of concomitant drugs. ( 5.1 , 5.3 , 7.1 , 7.2 , 7.3 ) LIVTENCITY has the potential to increase the drug concentrations of certain immunosuppressant drugs where minimal concentration changes may lead to serious adverse events (including tacrolimus, cyclosporine, sirolimus and everolimus).
Source: FDA drug label (Livtencity), Takeda Pharmaceuticals America, Inc., effective January 27, 2026 (SPL set c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0), via openFDA; the full label on DailyMed
What does the sirolimus label say about maribavir?
Sirolimus's label (effective January 28, 2026) and its 3 other brand-application labels do not name maribavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (sirolimus), Glenmark Pharmaceuticals Inc., USA, effective January 28, 2026 (SPL set 57fb4d90-3ccb-4a69-af1e-53be83f7a504), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Maribavir | Sirolimus | |
|---|---|---|
| Labeled for | n/a | Organ transplant rejection |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.723 per tablet 1 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once